Fig. 4From: A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trialAmerican College of Rheumatology (ACR) response rates by assessment group and somatization comorbidity phenotype (SCP) status. a ACR20. b ACR50. c ACR70. Full analysis set. Missing data were handled by non-responder imputationBack to article page